154 related articles for article (PubMed ID: 37011526)
1. Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE).
Demarest S; Jeste S; Agarwal N; Arkilo D; Asgharnejad M; Hsiao S; Thibert R
Epilepsy Behav; 2023 May; 142():109173. PubMed ID: 37011526
[TBL] [Abstract][Full Text] [Related]
2. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
[TBL] [Abstract][Full Text] [Related]
3. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
Halford JJ; Sperling MR; Arkilo D; Asgharnejad M; Zinger C; Xu R; During M; French JA
Epilepsy Res; 2021 Aug; 174():106646. PubMed ID: 33940389
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
Knight EMP; Amin S; Bahi-Buisson N; Benke TA; Cross JH; Demarest ST; Olson HE; Specchio N; Fleming TR; Aimetti AA; Gasior M; Devinsky O;
Lancet Neurol; 2022 May; 21(5):417-427. PubMed ID: 35429480
[TBL] [Abstract][Full Text] [Related]
5. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Devinsky O; Verducci C; Thiele EA; Laux LC; Patel AD; Filloux F; Szaflarski JP; Wilfong A; Clark GD; Park YD; Seltzer LE; Bebin EM; Flamini R; Wechsler RT; Friedman D
Epilepsy Behav; 2018 Sep; 86():131-137. PubMed ID: 30006259
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.
Olson HE; Amin S; Bahi-Buisson N; Devinsky O; Marsh ED; Pestana-Knight E; Rajaraman RR; Aimetti AA; Rybak E; Kong F; Miller I; Hulihan J; Demarest S
Epilepsia; 2024 Jan; 65(1):37-45. PubMed ID: 37950390
[TBL] [Abstract][Full Text] [Related]
7. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
8. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open-label exploratory trial.
Auvin S; Arzimanoglou A; Beller C; Floricel F; Daniels T; Bozorg A
Epilepsia; 2023 Nov; 64(11):2947-2957. PubMed ID: 37545406
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
[TBL] [Abstract][Full Text] [Related]
12. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY
Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
[TBL] [Abstract][Full Text] [Related]
14. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
Resnick T; Patten A; Ngo LY; Malhotra M
Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL; Klein P; Brandt C; Lee SK; Milanov I; Milovanovic M; Steinhoff BJ; Kamin M
Lancet Neurol; 2020 Jan; 19(1):38-48. PubMed ID: 31734103
[TBL] [Abstract][Full Text] [Related]
16. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
[TBL] [Abstract][Full Text] [Related]
17. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial.
Inoue Y; Liao W; Wang X; Du X; Tennigkeit F; Sasamoto H; Osakabe T; Hoshii N; Yuen N; Hong Z
Epilepsy Res; 2021 Oct; 176():106705. PubMed ID: 34246118
[TBL] [Abstract][Full Text] [Related]
19. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial.
O'Brien TJ; Borghs S; He QJ; Schulz AL; Yates S; Biton V
Epilepsia; 2020 Apr; 61(4):636-646. PubMed ID: 32221987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
